2:21
ESH MM 2018 | Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos
3:08
EHA 2018 | Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel
1:22
EHA 2018 | The importance of MRD status in MM
Niels van de Donk
1:54
ASH 2017 | CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
2:42
ASH 2017 | Promising results for daratumumab in the front line setting
Philippe Moreau
3:22
BOPA 2017 | Unprecedented clinical trial results for MM
Alberto Rocci
3:34
COMy 2017 | How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau
1:56
COMy 2017 | Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos
2:13
BSH 2017 | Daratumumab in the treatment of multiple myeloma
Paul Richardson
3:19
COMy 2017 | What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Nikhil Munshi
4:43
ASH 2016 | Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
4:11
ASCO 2016 | Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Joseph Mikhael
3:51
EHA 2016 | Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
2:58
EHA 2016 | Why daratumumab is effective in multiple myeloma – results from the CASTOR trial
Antonio Palumbo
3:12
EHA 2016 | Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje
4:04
EHA 2016 | Why daratumumab will become key for the treatment of multiple myeloma
Philippe Moreau
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals